Ultrasound in the Assessment of Tumor Response in the Age of Targeted and Immuno-Oncology Therapies. Back to the Future
- Weitere Titel
-
Ultraschall zur Bewertung des Tumor-Ansprechens im Zeitalter der zielgerichteten Therapien und der Immunonkologie – Zurück in die Zukunft („Back to the Future“)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Ultrasound in the Assessment of Tumor Response in the Age of Targeted and Immuno-Oncology Therapies. Back to the Future ; volume:40 ; number:02 ; year:2019 ; pages:129-131
Ultraschall in der Medizin ; 40, Heft 02 (2019), 129-131
- Beteiligte Personen und Organisationen
-
Tovoli, Francesco
Piscaglia, Fabio
Brkljacic, Boris
Cantisani, Vito
- DOI
-
10.1055/a-0834-8353
- URN
-
urn:nbn:de:101:1-2019061208560084371219
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tovoli, Francesco
- Piscaglia, Fabio
- Brkljacic, Boris
- Cantisani, Vito
Ähnliche Objekte (12)
Targeted Therapies in Pediatric Oncology
The management of cancer in the elderly: targeted therapies in oncology
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
Immuno-oncology
Immuno-Oncology
Personalized Immuno-Oncology
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance
Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
Targeted oncology
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Targeted Therapies in Pediatric Oncology
The management of cancer in the elderly: targeted therapies in oncology
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
Immuno-oncology
Immuno-Oncology
Personalized Immuno-Oncology
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance
Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
Targeted oncology
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Targeted Therapies in Pediatric Oncology
The management of cancer in the elderly: targeted therapies in oncology
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
Immuno-oncology
Immuno-Oncology
Personalized Immuno-Oncology
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance
Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
Targeted oncology
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art